SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (NASDAQ:BNGO) announced today that, in accordance with Nasdaq Listing Rule 5635(c)(4), the Compensation Committee of its Board of Directors granted the following non-qualified stock options pursuant to the company's 2020 Inducement Plan to new employees as an inducement material to such employees entering into employment with the Company:
- To Christopher Stewart, Bionano's Chief Financial Officer, an option to purchase up to 350,000 shares of common stock and a separate option to purchase up to 225,000 shares of common stock. The shares subject to the first option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the September 1, 2020 vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. The shares subject to the second option will vest in full on December 31, 2020. The vesting of each of the foregoing options is subject to continuous service through each applicable vesting date and acceleration of vesting as set forth in Mr. Stewart's employment agreement.
- To Alka Chaubey, Ph.D., Bionano's Chief Medical Officer, an option to purchase up to 300,000 shares of common stock. The shares subject to the …
Full story available on Benzinga.com